Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 1/20 | 0.34 |
| ▸ | CDK8 | P49336 | 1/20 | 0.34 |
| ▸ | CLK2 | P49760 | 1/20 | 0.34 |
| ▸ | CDK7 | P50613 | 1/20 | 0.34 |
| ▸ | CDK9 | P50750 | 1/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.32 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1269052 | 0.77 | APP (0.43) | MAP4K4CDK8CLK2CDK7CDK9 | |
| SCHEMBL21886164 | 0.77 | FGFR1 (0.39) | — | |
| SCHEMBL28055645 | 0.73 | GLO1 (0.37) | MAP4K4CDK8CLK2CDK7CDK9 | |
| SCHEMBL21958555 | 0.72 | DGAT1 (0.38) | MAP4K4CDK8CLK2CDK7CDK9 | |
| SCHEMBL522712 | 0.70 | MAP4K4 (0.30) | MAP4K4CDK8CLK2CDK7CDK9 | |
| SCHEMBL17253109 | 0.69 | DGAT1 (0.37) | — | |
| SCHEMBL28439760 | 0.68 | SLC22A12 (0.38) | — | |
| SCHEMBL18346376 | 0.66 | CYP2C19 (0.61) | — | |
| SCHEMBL12146970 | 0.65 | PARP1 (0.50) | MAPT | |
| SCHEMBL16452853 | 0.65 | GAA (0.39) | DYRK1ADYRK1BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190185471-A1 | SOLID FORMS OF VENETOCLAX AND PROCESSES FOR THE PREPARATION OF VENETOCLAX | DR. REDDY'S LABORATORIES LIMITED (IN) | 2019-06-20 | — | — | US | disclosed |
| WO-2017212431-A1 | SOLID FORMS OF VENETOCLAX AND PROCESSES FOR THE PREPARATION OF VENETOCLAX | DR. REDDY’S LABORATORIES LIMITED (IN) | 2017-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190185471-A1 | SOLID FORMS OF VENETOCLAX AND PROCESSES FOR THE PREPARATION OF VENETOCLAX | MCL1, PROC, U2AF1 | MAP4K4 2051/4885CDK8 611/4885CLK2 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.